Provided herein are adenoviral nucleic acid sequences and adenoviral vectors comprising said nucleic acid sequences. The provided adenoviral vectors can be used to induce a protective immune response in a subject.

This invention relates generally to compositions for making C A Vectors and uses thereof.

This invention relates generally to pharmaceutical compositions and preparations of curons and uses thereof.

The disclosure provides Cas12f polypeptides, fusion proteins comprising such Cas12f polypeptides, CRISPR-Cas12f systems comprising such Cas12f polypeptides or fusion proteins, and methods of using the same.

Disclosed herein are methods of treatment for an intraocular pressure (IOP)-associated condition in a subject, that include administering to the subject an effective amount of a tissue plasminogen activator (tPA) therapeutic agent. In one embodiment, the IOP-associated condition is glaucoma. The administration of a tPA therapeutic agent can be an extended administration intended to cause a reduction in IOP in the subject for a period of at least one day to a year or more, relative to IOP levels in the subject prior to administration of the tPA therapeutic agent. The tPA therapeutic agent can be, for example, tPA, a tPA derivative, a small molecule direct or indirect tPA agonist, or a gene therapy vector.

This invention relates generally to viral vectors and viral particles based on Anelloviruses, which can be used to deliver an agent (e.g., an exogenous effector or an endogenous effector, e.g., a therapeutic effector) to a cell (e.g., a cell in a subject to be treated therapeutically). Described herein are anellosomes, anellovectors, and compositions and uses thereof.

This invention relates generally to pharmaceutical compositions and preparations of curons and uses thereof.

This invention relates generally to compositions for making and administering anellovectors and uses thereof.

Disclosed herein are an infectious clone capable of inoculating Nanovirus DNA-C, DNA-M, DNA-N, and DNA-U1, and uses thereof. A recombinant vector comprising the nucleotide sequences of Nanovirus DNA-C, DNA-M, DNA-N, and DNA-U1 represented by SEQ ID NOS: 1 to 8, and E. coli and Agrobacterium tumefaciens, each transformed therewith, can effectively induce the infection of Nanovirus into crops even without any insect vectors. Therefore, the disclosure can be applied to various studies, such as investigating the host range and the correlation with hosts of Nanovirus DNA-C, DNA-M, DNA-N, and DNA-U1. This can help in preemptively preventing economic losses due to virus infections, making it beneficially applicable in the related fields.

This invention relates generally to pharmaceutical compositions and preparations of curons and uses thereof.